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Objectives: We evaluated the effect of an antibiotic stewardship programme (ASP) on the use of antibiotics and
resistance levels of Escherichia coli using a method that allowed direct comparison between an intervention
hospital and a control hospital.
Methods: The study was conducted as a retrospective controlled interrupted time series (ITS) at two university
teaching hospitals, intervention and control, with 736 and 552 beds, respectively. The study period was between
January 2008 and September 2014. We used ITS analysis to determine significant changes in antibiotic use
and resistance levels of E. coli. Results were directly compared with data from the control hospital utilizing a
subtracted time series (STS).
Results: Direct comparison with the control hospital showed that the ASP was associated with a significant
change in the level of use of cephalosporins [2151 DDDs/1000 bed-days (95% CI 2177, 2126)] and fluoroqui-
nolones [244.5 DDDs/1000 bed-days (95% CI 258.9, 230.1)]. Resistance of E. coli showed a significant
change in slope for cefuroxime [20.13 percentage points/month (95% CI 20.21, 20.057)] and ciprofloxacin
[20.15 percentage points/month (95% CI 20.26, 20.038)].
Conclusions: The ASP significantly reduced the use of cephalosporins and fluoroquinolones, with concomitant
decreasing levels of E. coli resistance to cefuroxime and ciprofloxacin. The same development was not observed
at the control hospital.
Introduction
Clinically relevant outcome measures of the effects of antibiotic
stewardship programmes (ASPs) are needed for use as quality
indicators. Professionals, administrators and authorities request
such outcome measures1 and they are of utmost importance to
ensure sustainable effects of ASPs,2 as well as for the general
acceptance of such programmes. However, evaluating and
reporting the effect of ASPs is not without challenges and there
are several pitfalls, including a lack of control groups.3
We implemented an ASP to curb increasing problems with MDR
organisms. The ASP focused on reducing the use of cephalospor-
ins and fluoroquinolones. A nearby comparable hospital that was
not part of the programme served as a control hospital.
This study evaluates the outcomes of the ASP by investigating
its impact on the resistance of E. coli to cefuroxime and
ciprofloxacin. We used a method that allowed direct comparison
between the intervention hospital and the control hospital in an
interrupted time series (ITS) analysis.
Materials and methods
Design and setting
This study was conducted as a retrospective ITS analysis in accordance
with the ORION guidelines,4 with a pre-implementation phase from
January 2008 to December 2010, an implementation phase from January
to December 2011 and a post-implementation phase from January 2012
to September 2014. It took place in the Capital Region of Denmark at
Herlev Hospital (intervention) and Hvidovre Hospital (control). For further
details of the hospitals see Table S1 (available as Supplementary data at
JAC Online). The study was approved by the Danish Data Protection Agency
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(record number HEH-2013-025-02269) and the Danish National Board of
Health (record number 3-3013-469/1/SMFS).
Intervention
The ASP was implemented during January–December 2011 and consisted
of multiple parts, but it primarily provided new antibiotic guidelines for
empirical treatment replacing cephalosporins and fluoroquinolones with
narrow-spectrum penicillins and gentamicin.5 For further details see
Table S2.
Laboratory procedures
Identification of microorganisms was performed using standard meth-
ods6 and susceptibility testing was performed by disc diffusion methods
according to EUCAST recommendations.7 We included E. coli isolates
from all types of specimens, but excluded isolates from primary care.
When multiple identical isolates from the same patient occurred within
a 30 day window, only the first isolate was used. From March 2012 to
June 2013, the intervention hospital temporarily changed susceptibility
testing of ciprofloxacin. To adjust for this change, we re-tested all blood
cultures of E. coli from this period. Therefore, during this period we calcu-
lated the level of resistance to ciprofloxacin at the intervention hospital
using only results from the re-tested blood cultures.
Outcomes
Our primary outcomes were change in use of cephalosporins and fluoro-
quinolones and resistance of E. coli to cefuroxime and ciprofloxacin. We
determined antibiotic use by adjusting the monthly use of antibiotics
(sales data) for changes in the number of occupied bed-days and
expressed it as DDDs per 1000 occupied bed-days. DDDs were defined
according to ATC/DDD index 2014.8 We expressed resistance as the per-
centage of resistant isolates out of the total number of isolates that
were tested for the specific resistance.
Statistical methods
We discarded observations from the implementation phase from the ana-
lysis, according to the method described by Cochrane Effective Practice
and Organisation of Care.9 To estimate how the hospitals differed before
and after the implementation, we performed an ITS analysis of the differ-
ence in outcomes at the two hospitals by subtracting data points of the
control hospital from data points of the intervention hospital for each
month, yielding a subtracted time series (STS). An analysis excluding the
Department of Haematology and the ICU was performed (Table S3). We
used the proc autoreg function in SAS 9.4 to test (using Durbin–Watson
statistics) and adjust for autocorrelation in order to estimate to the final
model parameters. To control for seasonality, we used stepwise autore-
gression with the NLAG option set to 13.10
Results
Implementing the ASP was associated with a significant decrease
in the use of cephalosporins at the intervention hospital [2150
(95% CI 2172, 2128) DDDs/1000 bed-days], but not at the con-
trol hospital (Table 1 and Figure 1). After the ASP’s implementa-
tion, the slope changed significantly at the control hospital,
resulting in a decrease in the use of cephalosporins, but not at
Table 1. ITS analysis of antibiotic use and resistance of E. coli at Herlev Hospital (intervention) and Hvidovre Hospital (control), with a direct comparison of
the two hospitals in the STS
Pre-implementation slope
Change in level
(implementation period) Change in slope
Monthly change in DDDs/1000
bed-days (95% CI)
Change in DDDs/1000 bed-days
(95% CI)
Monthly change in DDDs/1000
bed-days (95% CI)
Cephalosporins intervention 0.44 (20.24, 1.12) 2150 (2172, 2128)** 20.57 (21.52, 0.38)
control 1.15 (0.42, 1.87)* 1.14 (221.2, 23.5) 23.19 (24.28, 22.10)**
STS 20.82 (21.63, 20.006)* 2151 (2177, 2126)** 2.77 (1.58, 3.96)**
Fluoroquinolones intervention 20.10 (20.56, 0.36) 238.5 (252.9, 224.1)** 0.15 (20.52, 0.83)
control 0.060 (20.44, 0.56) 8.61 (24.33, 21.5) 20.41 (21.22, 0.39)
STS 20.27 (20.73, 0.18) 244.5 (258.9, 230.1)** 0.67 (20.011, 1.33)
Penicillins/BLIs intervention 0.58 (20.31, 1.48) 109 (82.6, 136)** 20.91 (22.27, 0.44)
control 0.51 (0.086, 0.93)* 24.39 (217.8, 8.99) 0.80 (0.19, 1.40)*
STS 0.10 (20.70, 0.91) 112 (88.0, 136)** 21.70 (22.92, 20.48)*









E. coli resistance, cefuroxime intervention 0.068 (0.021, 0.12)* 0.25 (21.17, 1.66) 20.11 (20.18, 20.041)*
control 0.031 (20.019, 0.080) 1.17 (20.32, 2.66) 0.016 (20.59, 0.091)
STS 0.054 (0.0008, 0.11)* 21.47 (23.14, 0.19) 20.13 (20.21, 20.057)*
E. coli resistance, ciprofloxacin intervention 0.13 (0.055, 0.21)* 5.43 (3.06, 7.80)** 20.25 (20.36, 20.15)**
control 0.13 (0.087, 0.17)** 2.18 (0.86, 3.50)* 20.10 (20.16, 20.041)*
STS 0.0070 (20.069, 0.083) 2.90 (0.50, 5.29)* 20.15 (20.26, 20.038)*














































































































































































































Figure 1. Use of cephalosporins and fluoroquinolones compared with resistance of E. coli to cefuroxime and ciprofloxacin. Use of cephalosporins at (a)
the intervention hospital and (b) the control hospital. Resistance of E. coli to cefuroxime at (c) the intervention hospital and (d) the intervention hospital.
Use of fluoroquinolones at (e) the intervention hospital and (f) the control hospital. Resistance of E. coli to ciprofloxacin at (g) the intervention hospital
and (h) the control hospital.
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the intervention hospital, resulting in a difference of 2.77 (95% CI
1.58, 3.96) DDDs/1000 bed-days in the direct comparison.
Resistance to cefuroxime was increasing at both hospitals
prior to 2011. The STS indicated that the increase was significantly
higher at the intervention hospital [0.054 (95% CI 0.0008, 0.11)
percentage points]. We observed no change at either hospital
during the implementation. After the implementation, the
slope changed significantly at the intervention hospital [20.11
(95% CI 20.18, 20.041) percentage points], but not at the control
hospital, resulting in a decrease in resistance at the intervention
hospital, but a continuous increase at the control hospital.
For fluoroquinolones, the ASP resulted in a significant reduction
in use at the intervention hospital [238.5 (95% CI 252.9, 224.1)
DDDs/1000 bed-days], but no significant change at the control
hospital. No changes were observed after implementation.
The resistance levels of E. coli increased significantly at both
hospitals prior to 2011. During the implementation, we observed
significant increases in resistance level at both hospitals. After
the implementation, the slope changed significantly at both
hospitals, resulting in a decreasing trend in resistance at the inter-
vention hospital and a reduction in slope at the control hospital.
The STS supported this by indicating a significant decrease
in the difference between the two hospitals [20.15 (95%
CI 20.26, 20.038) percentage points for ciprofloxacin].
During implementation we observed an unintended increase in
the use of penicillins in combination with b-lactamase inhibitors
[penicillins/b-lactamase inhibitors (BLIs)] at the intervention hos-
pital of 112 (95% CI 88.0, 136) DDDs/1000 bed-days when com-
pared with the control. For ITS analysis of other antibiotics, see
Table S4.
Discussion
The purpose of this study was to evaluate the effect of an ASP on
the use of antibiotics and resistance levels of E. coli. We observed
a significant and sustained reduction in the use of cephalosporins
and fluoroquinolones when compared with the control. After the
ASP’s implementation, resistance to both antibiotics decreased
significantly when directly compared with the control hospital.
However, during implementation, we also observed an unex-
pected increase in the use of penicillins/BLIs, which could be a
risk factor of Clostridium difficile infections (CDIs).11
A previous study has shown similar results regarding antibiotic
use and the development of resistance in E. coli, but did not use a
control for direct comparison.12 Another study has shown similar
results with regard to cefuroxime use, but not with E. coli, which
may be explained by the focus in that study on ESBL only.13 Only a
few other studies have used resistance in E. coli as an outcome,
but have not reported any positive effect on resistance.14,15
We chose E. coli because it is prevalent and causes clinically
relevant infections. The disadvantage of E. coli was the small dif-
ference in resistance levels between primary and secondary care
in our setting,16 giving a small margin of improvement, assuming
that resistance levels will not fall below those in primary care.
During the study period, the use of cephalosporins and fluoroqui-
nolones remained constant in primary care.16
The impact of ASPs at hospital level is difficult to document,
since contemporary hospital systems are constantly changing
and ASPs are often implemented to curb abrupt changes in anti-
microbial resistance.3 Since hospital use of antibiotics in general
only accounts for a small proportion of their total use, ASPs
have only limited effect on resistance in primary care, and the
impact of the ASP must be considered relative to the resistance
level in the community.16 To overcome these obstacles, we used
STS to determine whether the ASP caused significant differences
between the hospitals, thereby adjusting for changes in primary
care. This method has previously been described in other contexts,
but, to our knowledge, has not previously been used for the evalu-
ation of ASPs.17 – 19
Our study has strengths and weaknesses. We used STS, which
enabled direct comparison between the two hospitals. We had a
long study period and we included the entire hospital in the ana-
lysis. However, we did not distinguish between nosocomial and
community-acquired infections, as this would be adjusted for by
comparing the two hospitals assuming they have similar distribu-
tion between nosocomial and community-acquired infections.
Higher ciprofloxacin resistance may have occurred because only
re-tested blood cultures were used from March 2012 to June
2013, since E. coli isolates from blood cultures in Denmark have
a higher resistance than those from urine.16 We do not believe
that the spill-over effect of cephalosporin use affected the anti-
biotic use of the control hospital, since the change happened
late in the study period and after the ASP’s implementation.
Changes in infection control to curb an increase in CDIs were
implemented at both hospitals in 2011 –12. These changes
focused on controlling CDIs, and we do not believe that they influ-
enced the spread of antimicrobial-resistant E. coli. The study was
conducted in a setting with low levels of antibiotic resistance and
may not be generalizable to settings with higher resistance.
In conclusion, the introduction of an ASP was associated with a
significantly reduced use of cephalosporins and fluoroquinolones,
with concomitant decreasing resistance of E. coli to cefuroxime
and ciprofloxacin. The same development was not observed at
the control hospital.
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